S&P 500   3,604.50 (+0.75%)
DOW   29,917.03 (+1.10%)
QQQ   290.78 (+0.13%)
AAPL   112.99 (-0.76%)
MSFT   209.18 (-0.44%)
FB   268.71 (+0.10%)
GOOGL   1,731.85 (+0.25%)
AMZN   3,093.80 (-0.15%)
TSLA   530.10 (+1.58%)
NVDA   517.91 (-1.46%)
BABA   274.37 (+1.58%)
CGC   26.53 (+7.32%)
GE   10.67 (+5.96%)
MU   63.23 (-1.48%)
AMD   83.56 (-2.05%)
T   29.15 (+1.85%)
NIO   53.16 (-4.01%)
F   9.22 (+4.06%)
ACB   8.90 (+23.96%)
NFLX   476.80 (+0.04%)
GILD   59.97 (+0.13%)
BA   221.10 (+4.52%)
DIS   149.88 (+2.67%)
S&P 500   3,604.50 (+0.75%)
DOW   29,917.03 (+1.10%)
QQQ   290.78 (+0.13%)
AAPL   112.99 (-0.76%)
MSFT   209.18 (-0.44%)
FB   268.71 (+0.10%)
GOOGL   1,731.85 (+0.25%)
AMZN   3,093.80 (-0.15%)
TSLA   530.10 (+1.58%)
NVDA   517.91 (-1.46%)
BABA   274.37 (+1.58%)
CGC   26.53 (+7.32%)
GE   10.67 (+5.96%)
MU   63.23 (-1.48%)
AMD   83.56 (-2.05%)
T   29.15 (+1.85%)
NIO   53.16 (-4.01%)
F   9.22 (+4.06%)
ACB   8.90 (+23.96%)
NFLX   476.80 (+0.04%)
GILD   59.97 (+0.13%)
BA   221.10 (+4.52%)
DIS   149.88 (+2.67%)
S&P 500   3,604.50 (+0.75%)
DOW   29,917.03 (+1.10%)
QQQ   290.78 (+0.13%)
AAPL   112.99 (-0.76%)
MSFT   209.18 (-0.44%)
FB   268.71 (+0.10%)
GOOGL   1,731.85 (+0.25%)
AMZN   3,093.80 (-0.15%)
TSLA   530.10 (+1.58%)
NVDA   517.91 (-1.46%)
BABA   274.37 (+1.58%)
CGC   26.53 (+7.32%)
GE   10.67 (+5.96%)
MU   63.23 (-1.48%)
AMD   83.56 (-2.05%)
T   29.15 (+1.85%)
NIO   53.16 (-4.01%)
F   9.22 (+4.06%)
ACB   8.90 (+23.96%)
NFLX   476.80 (+0.04%)
GILD   59.97 (+0.13%)
BA   221.10 (+4.52%)
DIS   149.88 (+2.67%)
S&P 500   3,604.50 (+0.75%)
DOW   29,917.03 (+1.10%)
QQQ   290.78 (+0.13%)
AAPL   112.99 (-0.76%)
MSFT   209.18 (-0.44%)
FB   268.71 (+0.10%)
GOOGL   1,731.85 (+0.25%)
AMZN   3,093.80 (-0.15%)
TSLA   530.10 (+1.58%)
NVDA   517.91 (-1.46%)
BABA   274.37 (+1.58%)
CGC   26.53 (+7.32%)
GE   10.67 (+5.96%)
MU   63.23 (-1.48%)
AMD   83.56 (-2.05%)
T   29.15 (+1.85%)
NIO   53.16 (-4.01%)
F   9.22 (+4.06%)
ACB   8.90 (+23.96%)
NFLX   476.80 (+0.04%)
GILD   59.97 (+0.13%)
BA   221.10 (+4.52%)
DIS   149.88 (+2.67%)
Log in
NASDAQ:VIE

Viela Bio Stock Forecast, Price & News

$34.76
-0.22 (-0.63 %)
(As of 11/23/2020 12:00 AM ET)
Add
Compare
Today's Range
$34.43
Now: $34.76
$35.69
50-Day Range N/A
52-Week Range
$23.69
Now: $34.76
$70.66
Volume209,218 shs
Average Volume216,096 shs
Market Capitalization$1.91 billion
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Viela Bio, Inc., a clinical-stage biotechnology company, engages in the research and development of treatments for severe inflammation and autoimmune diseases in the United States. The company's lead product candidate is inebilizumab, a humanized monoclonal antibody for neuromyelitis optica spectrum disorder, kidney transplant desensitization, myasthenia gravis, and IgG4-related diseases. It is also developing VIB4920 for kidney transplantation rejection and sjögren's syndrome; and VIB7734 for cutaneous lupus erythematosus. Viela Bio, Inc. has a strategic collaboration with Mitsubishi Tanabe Pharma Corporation to develop and commercialize inebilizumab for autoimmune diseases in Japan, Thailand, South Korea, Indonesia, Vietnam, Malaysia, the Philippines, Singapore, and Taiwan. The company was founded in 2017 and is headquartered in Gaithersburg, Maryland.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 3.3Dividend Strength: 0.0Insider Behavior: 0.8Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.65 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:VIE
CUSIPN/A
CIKN/A
Phone240 558 0038
Employees152

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$50 million
Book Value$7.14 per share

Profitability

Net Income$-86,430,000.00

Miscellaneous

Market Cap$1.91 billion
Next Earnings Date3/24/2021 (Estimated)
OptionableNot Optionable
$34.76
-0.22 (-0.63 %)
(As of 11/23/2020 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive VIE News and Ratings via Email

Sign-up to receive the latest news and ratings for VIE and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Viela Bio (NASDAQ:VIE) Frequently Asked Questions

Do Wall Street analysts recommend investors buy shares of Viela Bio?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Viela Bio in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Viela Bio
.

What stocks does MarketBeat like better than Viela Bio?

Wall Street analysts have given Viela Bio a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's winning trading ideas this year have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Viela Bio wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Viela Bio's next earnings date?

Viela Bio is scheduled to release its next quarterly earnings announcement on Wednesday, March 24th 2021.
View our earnings forecast for Viela Bio
.

What price target have analysts set for VIE?

1 equities research analysts have issued 1-year price targets for Viela Bio's stock. Their forecasts range from $52.00 to $52.00. On average, they anticipate Viela Bio's stock price to reach $52.00 in the next year. This suggests a possible upside of 49.6% from the stock's current price.
View analysts' price targets for Viela Bio
.

Who are some of Viela Bio's key competitors?

Who are Viela Bio's key executives?

Viela Bio's management team includes the following people:
  • Dr. Zhengbin Yao, Chairman, Pres & CEO (Age 54, Pay $846.75k)
  • Mr. Mitchell Chan, Chief Financial Officer (Age 39, Pay $420.34k)
  • Dr. Aaron Ren M.B.A., Ph.D., VP and Head of Bus. Devel. & Operations (Age 43, Pay $385.63k)
  • Dr. Jörn Drappa M.D., Ph.D., Chief Medical Officer and Head of R&D (Age 55, Pay $637.39k)
  • Mr. James Paul Kastenmayer J.D., Ph.D., Gen. Counsel & Company Sec. (Age 48)
  • Ms. Kate Surdez, VP & Head of HR
  • Ms. Rachel Ettinger, Sr. Director & Head of Research
  • Mr. Bill Rees, Sr. Director & Head of Translational Science
  • Mr. Ted Phillips, VP & Head of Clinical Operations
  • Mr. Dewei She, Sr. Director and Head of Biostatistics, Data Management, & Programming

When did Viela Bio IPO?

(VIE) raised $150 million in an IPO on Thursday, October 3rd 2019. The company issued 7,500,000 shares at a price of $19.00-$21.00 per share. Goldman Sachs, Morgan Stanley and Cowen served as the underwriters for the IPO and Guggenheim Securities was co-manager.

What is Viela Bio's stock symbol?

Viela Bio trades on the NASDAQ under the ticker symbol "VIE."

How do I buy shares of Viela Bio?

Shares of VIE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Viela Bio's stock price today?

One share of VIE stock can currently be purchased for approximately $34.76.

How big of a company is Viela Bio?

Viela Bio has a market capitalization of $1.91 billion and generates $50 million in revenue each year. The company earns $-86,430,000.00 in net income (profit) each year or ($7.02) on an earnings per share basis. Viela Bio employs 152 workers across the globe.

What is Viela Bio's official website?

The official website for Viela Bio is www.vielabio.com.

How can I contact Viela Bio?

Viela Bio's mailing address is 1 MEDIMMUNE WAY, GAITHERSBURG MD, 20878. The company can be reached via phone at 240 558 0038 or via email at [email protected]

This page was last updated on 11/24/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.